A HER 1-2 Punch: Dual EGFR targeting deals resistance a deadly blow

Don L. Gibbons; Lauren Averett Byers

doi:10.1158/2159-8290.CD-14-0791

A HER 1-2 Punch: Dual EGFR targeting deals resistance a deadly blow

Don L. Gibbons, Lauren Averett Byers

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.

Original language	English (US)
Pages (from-to)	991-994
Number of pages	4
Journal	Cancer discovery
Volume	4
Issue number	9
DOIs	https://doi.org/10.1158/2159-8290.CD-14-0791
State	Published - Sep 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-14-0791

Cite this

@article{92415aa8ce264475a0dcb0c283b06682,

title = "A HER 1-2 Punch: Dual EGFR targeting deals resistance a deadly blow",

abstract = "Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.",

author = "Gibbons, {Don L.} and Byers, {Lauren Averett}",

year = "2014",

month = sep,

doi = "10.1158/2159-8290.CD-14-0791",

language = "English (US)",

volume = "4",

pages = "991--994",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "9",

}

TY - JOUR

T1 - A HER 1-2 Punch

T2 - Dual EGFR targeting deals resistance a deadly blow

AU - Gibbons, Don L.

AU - Byers, Lauren Averett

PY - 2014/9

Y1 - 2014/9

N2 - Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.

AB - Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84906914073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906914073&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0791

DO - 10.1158/2159-8290.CD-14-0791

M3 - Article

C2 - 25185188

AN - SCOPUS:84906914073

SN - 2159-8274

VL - 4

SP - 991

EP - 994

JO - Cancer discovery

JF - Cancer discovery

IS - 9

ER -

A HER 1-2 Punch: Dual EGFR targeting deals resistance a deadly blow

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this